Screener
TG Therapeutics TGTX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: TG Therapeutics’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 5:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025955
FAQ
- What is TG Therapeutics's cash & equivalents?
- TG Therapeutics (TGTX) reported cash & equivalents of $482.58M in Q2 2026.
- How has TG Therapeutics's cash & equivalents changed year-over-year?
- TG Therapeutics's cash & equivalents increased by 273.7% year-over-year, from $129.13M to $482.58M.
- What is the long-term trend for TG Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), TG Therapeutics's cash & equivalents has grown at a -32.2% compound annual growth rate (CAGR), from $553.44M to $79.15M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about TG Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude